Articles related to TARGETED THERAPIES

The inavolisib-based regimen more than doubled progression-free survival in PIK3CA-mutated breast cancers, offering a new standard of care for this challenging patient population.

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

The STRIDE regimen demonstrated a 30.7% survival rate at 36 months, compared to 20.2% with sorafenib, suggesting potential long-term benefits for patients with unresectable hepatocellular carcinoma.

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.